These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34119352)

  • 1. Oncolytic virotherapy in hematopoietic stem cell transplantation.
    Kazemi MH; Kuhestani Dehaghi B; Roshandel E; Parkhideh S; Mehdizadeh M; Salimi M; Hajifathali A; Hamidpour M
    Hum Immunol; 2021 Sep; 82(9):640-648. PubMed ID: 34119352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
    Zaghi E; Calvi M; Di Vito C; Mavilio D
    Front Immunol; 2019; 10():2794. PubMed ID: 31849972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
    Saha A; Blazar BR
    Front Immunol; 2022; 13():1031334. PubMed ID: 36341432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.
    Villa NY; Rahman MM; McFadden G; Cogle CR
    Viruses; 2016 Mar; 8(3):85. PubMed ID: 27011200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
    Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L
    Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
    Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
    Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications.
    Tsang JJ; Atkins HL
    Oncolytic Virother; 2015; 4():13-23. PubMed ID: 27512666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
    Xiong Y; Bensoussan D; Decot V
    Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.
    Blazar BR; Hill GR; Murphy WJ
    Nat Rev Clin Oncol; 2020 Aug; 17(8):475-492. PubMed ID: 32313224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin).
    Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y
    Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
    Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhu J; Chen J
    Mol Biol Rep; 2023 Mar; 50(3):2909-2917. PubMed ID: 36572760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.